- Income tax exemption for ten years.
- 6.5 million hectares (16.1 million acres) suitable for biofuel production.
- World’s fifth largest palm oil producer.
- Productivity of 9,000 liters of ethanol per hectare every year.
- Growing market. By 2020, a production of 1.4 billion liters of ethanol and 1.2 billion liters of biodiesel per year.
- Assured demand. In 2020, E20 and B20.
- Creation of a “green seal” to identify the national biofuel production with good environmental and social practices.
- Market of USD 2.6 million and production of USD 2.4 million.
- Cosmetics exports grew by 23% between 2003 and 2007.
- Country with the second largest flora biodiversity in Latin America.
- Market for men’s cosmetics is expected to grow 20% per year.
- Colombian women cosmetics pocket share duplicates the European average spending.
- More than 242,000 professionals and technicians available to work in the cosmetic industry.
- Manufactured products based on natural ingredients grew 9% between 2003 and 2008.
- Over 27,000 IT graduates and 13,000 engineering graduates per year.
- Seven cities with population over 500,000.
- Neutral Spanish-speaking accent.
- Market: USD 1 billion, growing at a rate of 42% for the past three years.
- 2.1 million foreign travellers visited Colombia in 2011.
- International tourism annual growth in Colombia (9.73%) more than doubled the worldwide growth (2%).
- Income tax exemption for new or remodeled hotels.
Medical and Health Tourism
- Pioneer Program in reproduction immunology; the first invitro fertilization baby born in Latin America; first pacemaker debveloped in the world.
- Colombia is the second best country for scientific and health infrastructure in Latin America: (IMD, 2008).
- 3,000 physicians and health professionals graduate from college each year.
In this Op-Ed piece in El Espectador, Rodrigo Lara states that regulation of biopharmaceuticals in Colombia will be heavily influenced by the interests of pharmaceutical companies, the FTA implementation process and USTR’s Special 301 Report. While provocative, the text misleads the reader to understand that Phrma’s input into the Special 301 report (http://bit.ly/dbb5P3) are the same as the recommendations issued through USTR’s final report (http://bit.ly/xp3C5f) . Article: http://bit.ly/zqWVSN
Article presents the positions of the four key players in the discussion to open the Colombian market to generic biotech: Multinational pharmceutical companies, local pharmaceutical companies, patient associations, national medicine academy, medical associations, Government of Colombia. http://bit.ly/yggYLs
First Post: Rodrigo Lara says biopharmaceuticals regulation will have an impact on FTA implementation
Fedesarrollo study shines light on overpricing and potential regulation of biopharmaceutical drugs http://bit.ly/AgpjzQ